Advantage Alpha Capital Partners LP Takes $245,000 Position in Eliem Therapeutics, Inc. (NASDAQ:ELYM)

Advantage Alpha Capital Partners LP acquired a new stake in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 48,169 shares of the company’s stock, valued at approximately $245,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ELYM. Rhumbline Advisers acquired a new position in shares of Eliem Therapeutics in the 2nd quarter valued at $59,000. SG Americas Securities LLC bought a new stake in Eliem Therapeutics in the third quarter valued at about $60,000. Valence8 US LP bought a new position in Eliem Therapeutics during the third quarter worth about $61,000. Chicago Partners Investment Group LLC bought a new position in Eliem Therapeutics during the third quarter worth about $81,000. Finally, Dimensional Fund Advisors LP acquired a new stake in Eliem Therapeutics during the second quarter valued at approximately $89,000. 69.76% of the stock is owned by institutional investors.

Eliem Therapeutics Trading Down 1.3 %

Shares of ELYM opened at $3.04 on Wednesday. The stock has a market cap of $90.45 million, a PE ratio of -5.81 and a beta of -0.39. Eliem Therapeutics, Inc. has a 1 year low of $2.35 and a 1 year high of $11.55. The stock has a 50 day simple moving average of $4.79 and a 200-day simple moving average of $6.52.

About Eliem Therapeutics

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.